» Articles » PMID: 11071633

High-level Transgene Expression in Human Hematopoietic Progenitors and Differentiated Blood Lineages After Transduction with Improved Lentiviral Vectors

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Nov 9
PMID 11071633
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Recent experiments point to the great value of lentiviral vectors for the transduction of human hematopoietic stem cells (hHSCs). Vectors used so far, however, have been poorly satisfying in terms of either biosafety or efficiency of transgene expression. Herein is described the results obtained with human immunodeficiency virus-based vectors optimized in both of these aspects. It is thus shown that vectors containing the EF1alpha and, to a lesser extent, the phosphoglycerate kinase (PGK) promoter, govern high-level gene expression in human hematopoietic progenitors as well as derived hematopoietic lineages of therapeutic relevance, such as erythrocytes, granulocytes, monocytes, dendritic cells, and megakaryocytes. EF1alpha promoter-containing lentiviral vectors can also induce strong transgene expression in primary T lymphocytes isolated from peripheral blood. A self-inactivating design did not affect the performance of EF1alpha promoter-based vectors but significantly reduced expression from the PGK promoter. This negative effect could nevertheless be largely rescued by inserting the post-transcriptional regulatory element of woodchuck hepatitis virus upstream of the vector 3' long terminal repeat. These results have important practical implications for the genetic treatment of lymphohematologic disorders as well as for the study of hematopoiesis via the lentivector-mediated modification of hHSCs.

Citing Articles

Optimization of a lentivirus-mediated gene therapy targeting HIV-1 RNA to eliminate HIV-1-infected cells.

Buckingham A, Ho S, Knops-Mckim F, Ingemarsdotter C, Lever A Mol Ther Nucleic Acids. 2024; 35(4):102341.

PMID: 39434850 PMC: 11491724. DOI: 10.1016/j.omtn.2024.102341.


A  transgene with enhanced therapeutic potential for the preclinical development of  gene therapy to treat mucopolysaccharidosis type IVB.

Crippa S, Alberti G, Passerini L, Savoia E, Mancino M, De Ponti G Mol Ther Methods Clin Dev. 2024; 32(3):101313.

PMID: 39282079 PMC: 11399592. DOI: 10.1016/j.omtm.2024.101313.


Determinants of Retroviral Integration and Implications for Gene Therapeutic MLV-Based Vectors and for a Cure for HIV-1 Infection.

Pellaers E, Bhat A, Christ F, Debyser Z Viruses. 2023; 15(1).

PMID: 36680071 PMC: 9861059. DOI: 10.3390/v15010032.


Mesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applications.

Belmar-Lopez C, Vassaux G, Medel-Martinez A, Burnet J, Quintanilla M, Cajal S Int J Mol Sci. 2022; 23(3).

PMID: 35163605 PMC: 8835939. DOI: 10.3390/ijms23031682.


A microRNA Cluster Controls Fat Cell Differentiation and Adipose Tissue Expansion By Regulating SNCG.

Rodriguez-Barrueco R, Latorre J, Devis-Jauregui L, Lluch A, Bonifaci N, Llobet F Adv Sci (Weinh). 2021; 9(4):e2104759.

PMID: 34898027 PMC: 8811811. DOI: 10.1002/advs.202104759.